TY - JOUR
T1 - Measurements of somatostatin-like immunoreactivity in plasma
AU - Harris, Virginia
AU - Conlon, J. Michael
AU - Srikant, Coimbatore B.
AU - McCorkle, Kay
AU - Schusdziarra, Volker
AU - Ipp, Eli
AU - Unger, Roger H.
N1 - Funding Information:
This work was supported by VA Institutional Research Support Grant 549-8000-01; NIH Grant AM 02700-16; NIH contract NOl-AM-62219; The Salk Institute Texas Research Foundation grant; Eli Lilly, Indianapolis, Indiana; CIBA-Geigy Pharmaceutical Company, Ardsley, New York; The Upjohn Company, Kalamazoo, Michigan; Bristol Myers Company, New York; and 30K Rabbit Fund.
Funding Information:
The authors wish to thank Drs. Akira Arimura, VA Hospital, New Orleans, Louisiana, and Wylie Vale, Salk Institute, La Jolla, California, for their generous gifts of antiserum. They also wish to thank The Medical Research Council, London, England, for the award of a Fellowship to J. Michael Conlon.
PY - 1978/7/15
Y1 - 1978/7/15
N2 - The validity of measurements of somatostatin-like immunoreactivity (SLI) in canine plasma has been examined. The radioimmunoassay employed had a minimal sensitivity of 50 pg/ml and a discriminatory sensitivity of 15 pg/ml above this. The coefficient of variation within and between assays was 6% and 18%, respectively. There was no cross-reaction with any of 9 other peptide hormones tested. Significant incubation damage by canine plasma to the [125I]-tyrosine1-somatostatin tracer was effectively prevented by Trasylol and EDTA, and recovery of synthetic somatostatin added to canine plasma and incubated for 3 h at 20°C was 96%. Subcutaneous injections of somatostatin were followed by a prompt rise in plasma SLI that was significantly correlated with decrease in plasma glucagon levels. Serial dilutions of plasma specimens containing high levels of either endogenous SLI or injected synthetic somatostatin gave proportional readings and their slopes paralleled those of synthetic somatostatin in plasma-free buffer. Ninety-five percent of endogenous plasma SLI was removed by passage of plasma specimens through a column of immobilized somatostatin antibodies. Both endogenous SLI in plasma and synthetic somatostatin added to plasma were eluted in the void volume of Biogel P-10 columns, but following isolation by affinity chromatography the molecular size of both was approx. 1600, suggesting that both endogenous SLI and synthetic somatostatin circulate in plasma bound to larger molecules. It is concluded that this radioimmunoassay permits valid measurements of endogenous SLI in canine plasma.
AB - The validity of measurements of somatostatin-like immunoreactivity (SLI) in canine plasma has been examined. The radioimmunoassay employed had a minimal sensitivity of 50 pg/ml and a discriminatory sensitivity of 15 pg/ml above this. The coefficient of variation within and between assays was 6% and 18%, respectively. There was no cross-reaction with any of 9 other peptide hormones tested. Significant incubation damage by canine plasma to the [125I]-tyrosine1-somatostatin tracer was effectively prevented by Trasylol and EDTA, and recovery of synthetic somatostatin added to canine plasma and incubated for 3 h at 20°C was 96%. Subcutaneous injections of somatostatin were followed by a prompt rise in plasma SLI that was significantly correlated with decrease in plasma glucagon levels. Serial dilutions of plasma specimens containing high levels of either endogenous SLI or injected synthetic somatostatin gave proportional readings and their slopes paralleled those of synthetic somatostatin in plasma-free buffer. Ninety-five percent of endogenous plasma SLI was removed by passage of plasma specimens through a column of immobilized somatostatin antibodies. Both endogenous SLI in plasma and synthetic somatostatin added to plasma were eluted in the void volume of Biogel P-10 columns, but following isolation by affinity chromatography the molecular size of both was approx. 1600, suggesting that both endogenous SLI and synthetic somatostatin circulate in plasma bound to larger molecules. It is concluded that this radioimmunoassay permits valid measurements of endogenous SLI in canine plasma.
UR - http://www.scopus.com/inward/record.url?scp=0017823375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017823375&partnerID=8YFLogxK
U2 - 10.1016/0009-8981(78)90348-0
DO - 10.1016/0009-8981(78)90348-0
M3 - Article
C2 - 657552
AN - SCOPUS:0017823375
SN - 0009-8981
VL - 87
SP - 275
EP - 283
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 2
ER -